Immunohistochemical phenotyping of T cells, granulocytes, and phagocytes in the muscle of cancer patients: association with radiologically defined muscle mass and gene expression.
Adaptive immunity
CD8 T cells
Cancer
Computed tomography
Granulocytes
Innate immunity
Muscle biopsy
Muscle catabolism
Muscle mass
Phagocytes
T cells
Journal
Skeletal muscle
ISSN: 2044-5040
Titre abrégé: Skelet Muscle
Pays: England
ID NLM: 101561193
Informations de publication
Date de publication:
14 09 2019
14 09 2019
Historique:
received:
18
04
2019
accepted:
16
08
2019
entrez:
16
9
2019
pubmed:
16
9
2019
medline:
6
5
2020
Statut:
epublish
Résumé
Inflammation is a recognized contributor to muscle wasting. Research in injury and myopathy suggests that interactions between the skeletal muscle and immune cells confer a pro-inflammatory environment that influences muscle loss through several mechanisms; however, this has not been explored in the cancer setting. This study investigated the local immune environment of the muscle by identifying the phenotype of immune cell populations in the muscle and their relationship to muscle mass in cancer patients. Intraoperative muscle biopsies were collected from cancer patients (n = 30, 91% gastrointestinal malignancies). Muscle mass was assessed histologically (muscle fiber cross-sectional area, CSA; μm T cells (CD3+), granulocytes/phagocytes (CD11b+), and CD3-CD4+ cells were identified. Muscle fiber CSA (μm The skeletal muscle immune environment of cancer patients is comprised of immune cell populations from the adaptive and innate immunity. Correlations of T cells, granulocyte/phagocytes, and CD3-CD4+ cells with muscle mass measurements indicate a positive relationship between immune cell numbers and muscle mass status in cancer patients. Further exploration with gene correlation analyses suggests that the presence of CD8 T cells is negatively correlated with components of muscle catabolism.
Sections du résumé
BACKGROUND
Inflammation is a recognized contributor to muscle wasting. Research in injury and myopathy suggests that interactions between the skeletal muscle and immune cells confer a pro-inflammatory environment that influences muscle loss through several mechanisms; however, this has not been explored in the cancer setting. This study investigated the local immune environment of the muscle by identifying the phenotype of immune cell populations in the muscle and their relationship to muscle mass in cancer patients.
METHODS
Intraoperative muscle biopsies were collected from cancer patients (n = 30, 91% gastrointestinal malignancies). Muscle mass was assessed histologically (muscle fiber cross-sectional area, CSA; μm
RESULTS
T cells (CD3+), granulocytes/phagocytes (CD11b+), and CD3-CD4+ cells were identified. Muscle fiber CSA (μm
CONCLUSION
The skeletal muscle immune environment of cancer patients is comprised of immune cell populations from the adaptive and innate immunity. Correlations of T cells, granulocyte/phagocytes, and CD3-CD4+ cells with muscle mass measurements indicate a positive relationship between immune cell numbers and muscle mass status in cancer patients. Further exploration with gene correlation analyses suggests that the presence of CD8 T cells is negatively correlated with components of muscle catabolism.
Identifiants
pubmed: 31521204
doi: 10.1186/s13395-019-0209-y
pii: 10.1186/s13395-019-0209-y
pmc: PMC6744687
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Subventions
Organisme : CIHR
ID : 142427
Pays : Canada
Organisme : CIHR
ID : 259704
Pays : Canada
Références
Am J Clin Nutr. 2013 Oct;98(4):1012-9
pubmed: 23966429
Tumour Biol. 2016 Aug;37(8):11359-64
pubmed: 26960692
J Biol Chem. 2015 Apr 24;290(17):11177-87
pubmed: 25787076
Brain Behav Immun. 2018 Oct;73:364-374
pubmed: 29852290
J Immunol. 2005 Dec 1;175(11):7093-7
pubmed: 16301610
Sci Rep. 2017 Oct 31;7(1):14470
pubmed: 29089584
J Immunol. 2012 Oct 1;189(7):3669-80
pubmed: 22933625
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
Biomed Res Int. 2014;2014:438675
pubmed: 25028653
Proc Nutr Soc. 2018 Nov;77(4):394-402
pubmed: 29708079
Arthritis Rheum. 2002 Apr;46(4):1044-55
pubmed: 11953983
Front Immunol. 2015 Oct 19;6:494
pubmed: 26539191
NPJ Precis Oncol. 2017 Aug 15;1(1):26
pubmed: 29872708
Autoimmun Rev. 2010 Apr;9(6):449-53
pubmed: 20026430
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Front Oncol. 2018 Oct 22;8:457
pubmed: 30460194
Ann Neurol. 1991 May;29(5):498-507
pubmed: 1830466
Sci Rep. 2017 May 23;7(1):2273
pubmed: 28536426
Surg Today. 1998;28(9):884-8
pubmed: 9744395
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Clin Nutr. 2018 Aug;37(4):1279-1285
pubmed: 28566220
Int J Biol Markers. 2000 Jan-Mar;15(1):22-5
pubmed: 10763136
Cell. 2002 Dec 13;111(6):837-51
pubmed: 12526810
Semin Cell Dev Biol. 2016 Jun;54:2-10
pubmed: 26343952
Skelet Muscle. 2012 Feb 07;2(1):3
pubmed: 22313861
Cancer Manag Res. 2018 Oct 25;10:4935-4944
pubmed: 30464594
J Immunol. 2013 Nov 1;191(9):4611-8
pubmed: 24078690
Am J Physiol Endocrinol Metab. 2006 May;290(5):E961-7
pubmed: 16352667
Haematologica. 2012 Jul;97(7):1080-4
pubmed: 22315492
Cell Death Dis. 2016 Feb 25;7:e2109
pubmed: 26913600
PLoS One. 2017 Jul 10;12(7):e0181086
pubmed: 28700655
PLoS One. 2013 Jun 03;8(6):e65380
pubmed: 23755224
Crit Rev Biochem Mol Biol. 2014 Jan-Feb;49(1):59-68
pubmed: 24237131
J Cachexia Sarcopenia Muscle. 2017 Feb;8(1):122-130
pubmed: 27897403
Blood. 2009 Oct 1;114(14):2969-83
pubmed: 19608752
Int J Biochem Cell Biol. 2016 Oct;79:462-468
pubmed: 27475983
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1356-1377
pubmed: 31307124
Nat Commun. 2015 Apr 10;6:6670
pubmed: 25858807
Br J Cancer. 2001 Apr 20;84(8):1135-40
pubmed: 11308266
Oncotarget. 2017 Mar 14;8(11):17475-17490
pubmed: 28407698
J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):405-416
pubmed: 28058815
Ann Surg. 2016 Feb;263(2):320-5
pubmed: 25643288
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Mol Cell Biol. 2016 Nov 14;36(23):2956-2966
pubmed: 27644327
Cancer Manag Res. 2018 Aug 07;10:2499-2507
pubmed: 30122999
Am J Clin Nutr. 2009 Apr;89(4):1173-9
pubmed: 19244378
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
Exp Hematol. 2009 Feb;37(2):266-75
pubmed: 19100676
Nat Rev Dis Primers. 2018 Jan 18;4:17105
pubmed: 29345251
J Physiol. 2010 Sep 1;588(Pt 17):3307-20
pubmed: 20624792
J Physiol. 2000 Nov 15;529 Pt 1:243-62
pubmed: 11080266
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):827-843
pubmed: 30977974
Ann Surg Oncol. 2017 Aug;24(8):2241-2251
pubmed: 28324283
J Immunol. 2004 Oct 1;173(7):4360-7
pubmed: 15383565
Br J Cancer. 2016 Mar 15;114(6):680-7
pubmed: 26954714
Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1263-9
pubmed: 18086970
Ann Surg Oncol. 2015 Jul;22(7):2416-23
pubmed: 25519927
Annu Rev Immunol. 2013;31:137-61
pubmed: 23215646
BMC Gastroenterol. 2018 Oct 11;18(1):148
pubmed: 30305076
Sci Rep. 2018 Jul 27;8(1):11369
pubmed: 30054580
Cancer Med. 2018 Aug;7(8):3537-3547
pubmed: 29953752
PLoS One. 2016 Aug 18;11(8):e0161125
pubmed: 27537502
N Engl J Med. 2015 Apr 30;372(18):1734-47
pubmed: 25923553
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
J Biol Chem. 2009 Sep 25;284(39):26964-77
pubmed: 19643733
J Biol Chem. 2004 Apr 23;279(17):17070-8
pubmed: 14764603
J Physiol. 2004 May 1;556(Pt 3):983-1000
pubmed: 14766942
Ann Rheum Dis. 2006 Dec;65(12):1565-71
pubmed: 16831829
J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):60-70
pubmed: 28984045
Curr Opin Oncol. 2013 Nov;25(6):637-45
pubmed: 24076584
Arthritis Res Ther. 2016 Apr 01;18:80
pubmed: 27039301
Nat Rev Immunol. 2012 Mar 16;12(4):306-15
pubmed: 22421787
Nat Rev Immunol. 2017 Mar;17(3):165-178
pubmed: 28163303
Arthritis Rheumatol. 2016 Aug;68(8):2016-26
pubmed: 26895511
Support Care Cancer. 2016 May;24(5):2075-2084
pubmed: 26546456